BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...research at the Novartis Institutes for BioMedical Research, is now EVP and CSO of UCB S.A. (Euronext:UCB).S1PR...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...than olanzapine alone while demonstrating comparable antipsychotic efficacy.UCB, Aetion partner to advance RWE capabilitiesUCB S.A. (Euronext:UCB...
...advance its real-world evidence capabilities in order to support its value-based agreements in the U.S. UCB...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...as the confirmatory trial following the therapy’s accelerated approval in December. UCB’s bimekizumab under review UCB S.A. (Euronext:UCB...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...Inc. (NASDAQ:PPD). The company, which is partnered with biopharmas including Novartis AG (NYSE:NVS; SIX:NOVN) and UCB S.A. (Euronext:UCB...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Shulman as SVP, technical operations. He held the same position at Ra Pharmaceuticals Inc., which UCB S.A....
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...Avelox moxifloxacin, a fluoroquinolone antibiotic from Bayer AG (Xetra:BAYN); seizure drug Keppra levetiracetam from UCB S.A. (Euronext:UCB...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...COVID-19 in November. Mummenbrauer expects the series A round -- which saw participation from VIB, UCB...
...to enable ExeVir to complete Phase II testing and seek conditional approval of XVR-011. UCB S.A. (Euronext:UCB...
...UCB S.A. (Euronext:UCB) Number of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB...
BioCentury | Jul 30, 2020
Deals

UCB deal gives Roche a second shot on goal with tau in Alzheimer’s

...Roche’s addition of UCB’s anti-tau mAb to its portfolio suggests the pharma’s strategy for the latest...
...up front; and up to nearly $2 billion in cost reimbursements, milestones and royalties. UCB S.A. (Euronext:UCB...
...of tau pathology. Subsequently, Genentech can choose to continue clinical development or return rights to UCB...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...will succeed Cynthia Ladd as general counsel. Waynick joins the cardiovascular diseases company from UCB S.A. (Euronext:UCB...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...at the American Society of Rheumatology meeting. Dapirolizumab pegol from Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB...
Items per page:
1 - 10 of 1351
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...research at the Novartis Institutes for BioMedical Research, is now EVP and CSO of UCB S.A. (Euronext:UCB).S1PR...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...than olanzapine alone while demonstrating comparable antipsychotic efficacy.UCB, Aetion partner to advance RWE capabilitiesUCB S.A. (Euronext:UCB...
...advance its real-world evidence capabilities in order to support its value-based agreements in the U.S. UCB...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...as the confirmatory trial following the therapy’s accelerated approval in December. UCB’s bimekizumab under review UCB S.A. (Euronext:UCB...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...Inc. (NASDAQ:PPD). The company, which is partnered with biopharmas including Novartis AG (NYSE:NVS; SIX:NOVN) and UCB S.A. (Euronext:UCB...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Shulman as SVP, technical operations. He held the same position at Ra Pharmaceuticals Inc., which UCB S.A....
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...Avelox moxifloxacin, a fluoroquinolone antibiotic from Bayer AG (Xetra:BAYN); seizure drug Keppra levetiracetam from UCB S.A. (Euronext:UCB...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...COVID-19 in November. Mummenbrauer expects the series A round -- which saw participation from VIB, UCB...
...to enable ExeVir to complete Phase II testing and seek conditional approval of XVR-011. UCB S.A. (Euronext:UCB...
...UCB S.A. (Euronext:UCB) Number of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB...
BioCentury | Jul 30, 2020
Deals

UCB deal gives Roche a second shot on goal with tau in Alzheimer’s

...Roche’s addition of UCB’s anti-tau mAb to its portfolio suggests the pharma’s strategy for the latest...
...up front; and up to nearly $2 billion in cost reimbursements, milestones and royalties. UCB S.A. (Euronext:UCB...
...of tau pathology. Subsequently, Genentech can choose to continue clinical development or return rights to UCB...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...will succeed Cynthia Ladd as general counsel. Waynick joins the cardiovascular diseases company from UCB S.A. (Euronext:UCB...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...at the American Society of Rheumatology meeting. Dapirolizumab pegol from Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB...
Items per page:
1 - 10 of 1351